Breathe Well Live Well
|
BRIEF-Japan approves GlaxoSmithkline's asthma drug Nucala
Reuters March 29 Glaxosmithkline Plc. * Receives marketing authorisation for nucala (mepolizumab) in Japan. * Nucala is licensed in japan for adults and adolescents aged 12 years or older Source text for Eikon: Further company coverage: (Reporting By London … |
View full post on asthma – Google News
Lung Disease News |
Glaxo's asthma drug Nucala gets Japanese approval
MarketWatch The Japanese Ministry of Health, Labour and Welfare granted approval for the drug "as a treatment for bronchial asthma in patients with refractory asthma whose symptoms are inadequately controlled with standard treatment," Glaxo said Tuesday. FDA Approves Teva's Asthma Drug Cinqair as Add-on Treatment GSK: Nucala Receives Approval In Japan For Treatment Of Bronchial Asthma Nucala and Cinqair for the Treatment of Severe Asthma |
View full post on asthma – Google News
|
GSK's First Biologic Treatment For Asthma – Nucala Holds Multi-Billion Dollar Potential
Seeking Alpha Nucala was recently approved by the USFDA and EMA for the treatment of patients with severe Asthma of eosinophilic phenotype. In the base case, Nucala should reach peak sales of $2b. If Nucala is approved in other indications (COPD, HES) too, it can … |
View full post on asthma – Google News
PMLiVE |
GSK's severe asthma therapy Nucala gets EU nod
PMLiVE GlaxoSmithKline's first-in-class interleukin-5 (IL-5) inhibitor Nucala has been approved in the EU as a steroid-sparing therapy for patients with severe asthma. Nucala (mepolizumab) has been cleared by the European Commission as an add-on treatment for … |
View full post on asthma – Google News
BioPharma-Reporter.com |
GSK set to kickstart asthma mAb sector after EU Nucala approval
BioPharma-Reporter.com This decline, coupled with the underperformance of more recently launched drugs – Breo and Anoro Ellipta – saw revenue generated by GSK's asthma franchise fall 10% to £6.1bn in 2014. GSK has not given a forecast for Nucala, but clearly it hopes the … |
View full post on asthma – Google News
Medscape |
EMA OKs Nucala for Severe Refractory Eosinophilic Asthma
Medscape The European Medicines Agency (EMA) has approved mepolizumab (Nucala, GlaxoSmithKline) as an add-on treatment for severe refractory eosinophilic asthma in adults in the 31 European countries covered by the EMA, according to a company statement. GSK gets European marketing rights for Nucala to treat asthma EU OK for GSK's novel asthma biologic Nucala Now Available for Severe Asthma |
View full post on asthma – Google News
The Pharma Letter (registration) |
GSK gets European marketing rights for Nucala to treat asthma
The Pharma Letter (registration) UK drug major GlaxoSmithKline (LSE: GSK) said the European Commission has granted marketing rights for its drug Nucala (mepolizumab) as an add-on treatment for asthma. Nucala is now approved for use in the 31 European countries covered by the … EU OK for GSK's novel asthma biologic Nucala Now Available for Severe Asthma EU Grants Marketing Authorization to GSK's Nucala |
View full post on asthma – Google News
Monthly Prescribing Reference (registration) |
Nucala Now Available for Severe Asthma
Monthly Prescribing Reference (registration) GlaxoSmithKline announced the launch of Nucala (mepolizumab) subcutaneous injection for the treatment of patients aged ?12 years with severe asthma with an eosinophilic phenotype. Nucala, the first biologic add-on therapy approved for this condition, … GSK Announces NucalaB. (mepolizumab), Now Available In The Us For Sub-Group Of … GSK Says Nucala Available In U.S. For Sub-group Of Patients With Severe Asthma |
View full post on asthma – Google News
|
Nucala approved to treat severe asthma
Examiner.com The FDA has approved Nucala (mepolizumab) for use with other asthma medicines for the maintenance treatment of asthma in patients age 12 years and older with a history severe attacks (exacerbations) despite receiving their current asthma medicines. |
View full post on asthma – Google News
International Business Times |
Glaxo's Injectable Asthma Treatment 'Nucala' Gets Approval From FDA
International Business Times The U.S. Food and Drug Administration (FDA) has given a go ahead to GlaxoSmithKline Plc's drug Nucala for treatment of severe asthma. The regulato6ry body said that the drug can be used in combination with other therapies and medications for asthma … FDA Approves New Asthma Medication Mepolizumab gets green signal from FDA to be used for maintenance treatment of … GlaxoSmithKline plc (ADR): Why Nucala's FDA Approval Is Significant |
View full post on asthma – Google News